Abstract Olfactory ensheathing cell (OEC) transplantation emerged some years ago as a promising therapeutic strategy to repair injured spinal cord. However, inhibitory molecules are present for long periods of time in lesioned spinal cord, inhibiting both OEC migration and axonal regrowth. Two families of these molecules, chondroitin sulphate proteoglycans (CSPG) and myelin-derived inhibitors (MAIs), are able to trigger inhibitory responses in lesioned axons. Mounting evidence suggests that OEC migration is inhibited by myelin. Here we demonstrate that OEC migration is largely inhibited by CSPGs and that inhibition can be overcome by the bacterial enzyme Chondroitinase ABC. In parallel, we have generated a stable OEC cell line overexpressing the Nogo receptor (NgR) ectodomain to reduce MAI-associated inhibition in vitro and in vivo. Results indicate that engineered cells migrate longer distances than unmodified OECs over myelin or oligodendrocyte-myelin glycoprotein (OMgp)-coated substrates. In addition, they also show improved migration in lesioned spinal cord. Our results provide new insights toward the improvement of the mechanisms of action and optimization of OEC-based cell therapy for spinal cord lesion.
Introduction
Spontaneous regeneration of damaged axons in the lesioned spinal cord is poor, often resulting in a permanent loss of motor and sensory function [1, 2] . The inhibitory environment for axonal regrowth generated by the meningo-glial scar is the main obstacle to regeneration after lesion [3] [4] [5] . Current strategies to enhance functional regeneration after spinal cord injury (SCI) include gene therapy, biochemical and/or pharmacological treatment, and cell transplantation [6] [7] [8] . In this scenario, olfactory ensheathing cells (OECs) have attracted particular attention as a therapeutic cell transplantation strategy [9, 10] . During mammalian lifespan, OECs are capable of ensheathing and guiding newly growing axons of olfactory sensory neurons from the olfactory mucosa to their targets in the CNS [11, 12] . Indeed, OECs have been successfully used in many transplantation experiments following SCI, with encouraging outcomes (e.g., [13] [14] [15] ). The precise mechanisms accounting for the observed recovery are not fully understood but may include promotion of axonal regeneration, remyelination, neuroprotection, and induction of neovascularization (see [9] for recent review). The migratory potential of OECs is crucial to their function [16] . However, studies of the migration capacity and behaviour of OECs after transplantation in SCI models have led to contradictory results [17] [18] [19] . Nevertheless, it has been demonstrated that in injured spinal cord, rat and human OECs migrate for shorter distances, in both rostral and caudal directions, compared to non-injured spinal cords [20] . At the molecular level, GDNF [21] , Slit-2 [22, 23] , NogoA [24, 25] and fibulin-3 [26] have been demonstrated to regulate OEC migration. In fact, we and others have demonstrated that the OEC migratory potential is largely impaired by myelin [24, 25, 27, 28] and that this inhibition may be partially overcome by treatment with NEP1-40 peptide [24] or antibodies against the myelin receptor Nogo receptor [25] . However, following SCI, myelin-associated inhibitors (MAIs) as well as chondroitin sulphate proteoglycans (CSPGs) and secreted semaphorins are overexpressed at the site of the lesion and they are exposed to lesioned axons for protracted times [29] [30] [31] . However, although OEC transplantation has been combined with enzymatic degradation of CSPGs [32] [33] [34] , whether CSPG and secreted semaphorins can also inhibit both axon regrowth and OEC migration is unknown.
In a previous study, we determined the effects of myelin extracts and CSPG on OEC migration, using video timelapse, traction force microscopy and biochemical methods [24] . In the present study, we analysed the behaviour of OECs cultured on CSPGs-or Oligodendrocyte-Myelin Glycoprotein (OMgp)-coated substrates. CSPG-mediated inhibition of OEC migration can be abolished using ChABC. In addition, we genetically modified a stable cell line of OECs (TEG3 cell line [35] ) to produce and secrete the extracellular domain of the Nogo receptor protein [NgR(Ecto)] to enhance migration in myelin-derived inhibitors. In fact, NgR(Ecto) is a truncated form of the receptor that binds to MAIs, preventing their binding to the NgR complex by interacting with full-length NgR1 and blocking the intracellular signalling of MAIs [36, 37] . Moreover, following SCI, intrathecal and intraperitoneal injections of NgR(Ecto) improved axon regeneration of transected axonal tracts and functional recovery [38, 39] . Our results demonstrate that NgR(Ecto)-expressing OECs migrated longer distances in vitro in comparison to nonmodified OECs. In addition, we show that after implantation in a lesioned spinal cord of adult rats, NgR(Ecto)-OECs also migrate longer distances than non-modified cells. Our results provide new insights toward improvement of the mechanisms of action and optimization of OEC-based cell therapy for SCI.
Methods

Antibodies and biochemical reagents
The following antibodies were used at a dilution of 1:500 for immunohistochemistry and/or western blotting: S100b and b3-Tubulin (TUJ-1, 1:4000) purchased from Abcam (Cambridge, MA, USA), glial fibrilary acidic protein (GFAP) and green fluorescence protein (GFP) antibodies from DAKO (Glostrup, Denmark), and p75 from Promega (Madison, WI, USA). NgR1 was a gift from B.L. Tang (Singapore). Alexa Fluor 488 goat anti-mouse and Alexa Fluor 568 goat anti-rabbit immunoglobulins were purchased from Molecular Probes (Leiden, Netherlands). The goat anti-mouse horseradish peroxidase (HRP) and rabbit anti-goat-HRP secondary antibodies used in Western blots were from DAKO. Tubulin (1:5,000), Phalloidin-Alexa 488, and DAPI were from Sigma (St. Louis, MO, USA). CSPG and OMgp proteins were purchased from R&D Systems (Minneapolis, MN, USA). Myelin extract was obtained as [40] and NogoA-containing membranes as [41] .
Cloning of the NgR ectodomain [NgR(Ecto)] and lentiviral production
The NgR(Ecto) construct ( Supplementary Fig. S1 ) was prepared as follows: the cDNA of the region was cloned by PCR from adult mouse brain with the primers: NgR(Ecto) Forward 5 0 -AAA GGA TCC ATG AAG AGG GCC TCC TCC GGA-3 0 , and NgR(Ecto) Reverse 5 0 -AAT GGA TCC TTA TCA AGC ACA ACC CTC TAA GTC ACT-3 0 . The NgR(Ecto) PCR fragment was extracted (QIAquick, QIA-GEN, Hilden, Germany) and subcloned into the pLenti6/ V5-DEST vector (Invitrogen, Grand Island, NY, USA) into ApaI and BclI sites. This NgR(Ecto) vector was then sequenced to ensure correct nucleotide sequence. Subsequently, lentiviral particles were produced by transient transfection of 293FT cells with Lipofectamine 2000 (Invitrogen), using the NgR(Ecto) vector, the second generation packaging construct psPAX (Tronolab, Lausanne, Switzerland) and the envelope plasmid pMD2G (Tronolab). 293FT cells (Invitrogen) were cultured in DMEM supplemented with 10 % foetaB calf serum and without antibiotics before transfection. Medium was changed and supplemented with antibiotics after 6 h. Medium supernatants containing viral particles were harvested 24 and 48 h later and concentrated by ultracentrifugation (2 h at 26,0009g at 4°C).
TEG3 cultures and infection strategy
The immortalized clonal cell line TEG3, which contains the SV40 large T antigen stable transfectant of OEG primary cultures, was used [35] . Cells were maintained in ME10: DMEM-F12 (Invitrogen) supplemented with 10 % bovine calf serum (SAFC Biosciences, Lanexa, VA, USA), 20 lg/ml pituitary extract (Invitrogen), 2 lM forskolin (Sigma), 1 % penicillin-streptomycin, and 1 % fungizone (Invitrogen). TEG3 cells were transfected using a lentivirus carrying the NgR(Ecto) construct and/or one lentivirus carrying the eGFP construct ( Supplementary Fig. S1 ). Cells in passage 2 were plated at 2,000 cells/cm 2 and incubated with one of the lentiviruses for 48 h. Then, the medium was changed and the cells cultured as described above with the addition of Blasticidin (3 lg/ml, Sigma) to the medium in the case of the NgR(Ecto). For double transfection, cells were first incubated with the NgR(Ecto) lentivirus, and afterwards with the eGFP. Single clones were selected with cloning disks (Sigma) and expression of NgR(Ecto) was tested in these clones by western blot. Selected clones were grown in ME10 media.
Immunocytochemical methods on TEG3 cells
Glass coverslips (12 mm diameter) were coated with proteins essentially as described [36] . Briefly, coverslips were pre-coated with Poly-L-Lysine 10 lg/ml dissolved in 0.1 M PBS (pH 7.3) and then washed. They were coated with laminin (2 lg/ml, dissolved in 0.1 M PBS) and washed again with 0.1 M PBS. NgR(Ecto)-TEG3 cells were seeded onto substrate-coated coverslips in ME10 medium. Cells were cultured for 20 h and then the coverslips were fixed in 4 % buffered paraformaldehyde for 30 min, permeabilized with 0.1 % Triton X-100, and blocked with 10 % normal serum in both diluted in 0.1 M PBS. Cells were sequentially incubated overnight with primary antibodies at 4°C and with Alexa Fluor-tagged secondary antibodies for 1 h. After rinsing in 0.1 M PBS, cells were stained with 0.1 M DAPI diluted in 0.1 M PBS for 10 min, rinsed in 0.1 M PBS, and mounted on Fluoromount TM (Vector Labs, Burlingame, CA, USA); they were then analysed using a fluorescence microscope equipped with a cooled camera (Olympus BX61 ? DP12L camera).
Nogo66-AP binding assays
Binding experiments were developed essentially as described [42] . TEG3 cells (75 % confluence) were fixed in methanol at -80°C for 5 min. After rehydrating in 0.1 M PBS, they were overlaid with different concentrations of Nogo66-AP (kindly provided by Zhigang He) diluted in Hanks Balanced Salt Solution (HBSS, Invitrogen) and 20 % FCS for 90 min, washed, and fixed in 3.7 % paraformaldehyde. Endogenous phosphatase was heat inactivated at 65°C. The AP-fusion protein was viewed through an enzymatic reaction with a solution containing In vitro experiments with cerebellar granule neurons (CGNs)
CGNs from P5-P7 mouse (CD1 strain, Charles River, Lyon, France) pups were dissociated by combined trypsinization as described previously [43] . Cells were placed in 24-well tissue culture dishes (Nunc, Roskilde, Denmark) on coated coverslips (see below) and grown for 24-48 h in DMEM medium supplemented with N2 and B27 (Invitrogen). The procedures were used to treat cells with MAIs or myelin; the cell surface was coated with purified myelin essentially as described [40] . In vitro experiment on microfluidic devices Embryonic cortical neurons were cultured in compartmented microchips (Cat. SND900, Xona TM microfluidics, Temecula, CA, USA) (see [44] for details). Both reservoirs (axonal and soma) were coated overnight with Poly-DLysine to ensure that the protein also coated the surface of the 900 lm long bridge channels. The following day the axonal compartment was also coated with OMgp as above. To avoid diffusion of the OMgp from the axonal to the soma compartment, a larger amount ([15 %) of medium was added to the soma compartment during the experiment. Cortical neurons were seeded and after an additional 2 days in vitro, eGFP-TEG3 or eGFP-NgR(Ecto)-TEG3 cells (2 9 10 5 ) were seeded in the axonal compartment. After an additional 10 days in vitro, microchips were fixed in 4 % buffered paraformaldehyde and rinsed in 0.1 M PBS. After rinsing in 0.1 M PBS, chips were incubated with TUJ-1 and eGFP antibodies for two days at 4 8C and 6 h with the appropriate Alexa-tagged secondary antibodies. After rinsing, both soma and axonal compartments were filled with Fluoromount TM in 0.1 M PBS (2:1 diluted) and photodocumented. The length of the cortical neurons in the axonal compartment was measured using ImageJ TM software. A total of 20 chips were analysed in each condition.
Traction force microscopy measurements
Cell tractions were evaluated using constrained Fourier transform traction microscopy (FTTM) [45] . PAA gels were coated with laminin, CSPG, or OMgp as described [24] , and cells were cultured over the PAA-coated gels. Briefly, to obtain a stiff gel of 12 kPa Young Modulus (PAA), 265 ll of an Acrylamide/Bis-acrylamide mixture (15 % Acrylamide and 6.5 % Bis-acrylamide, Bio-Rad) were dissolved in ultrapure water containing 0.4 % of 0.2 m diameter red fluorescent beads (Invitrogen), 0.5 % ammonia persulfate, and 0.05 % TEMED (Bio-Rad). For multi-tracking, the mixture was added to the centre of the dish, which was then coated and stored overnight at 4°C. The displacement field was calculated by comparing fluorescent microbead images obtained during the experiment with a reference image taken at the end of the experiment after the trypsinization and the consequent detachment of OECs from the underlying substrate. The projected cell area was calculated with Matlab TM , based on the manual tracing of the OEC contours determined by a phase contrast image obtained at the start of the experiment. A particle imaging velocimetry algorithm [46] was used to determine the deformation of the substrate caused by the traction forces. The number of analysed cells in each condition is indicated in the Results section.
Surgical procedures and cell transplantation
Adult female Sprague-Dawley rats (9 weeks old; 250-300 g weight) were used in the spinal cord experiments. The animals were housed with free access to food and water at room temperature of 22 ± 2°C under a 12:12 h light-dark cycle. The experimental procedures were approved by the ethical committee of the Universitat Autonoma de Barcelona and the IBEC in accordance with European Directive 86/609/EEC. Under anaesthesia with ketamine (90 mg/kg) and xylacine (10 mg/kg) and aseptic conditions, laminectomy was performed in T8-T9 vertebra and a cord contusion of 200 Kdyns was induced using an Infinite Horizon Impactor (Precision System and Instrumentation, Kentucky, USA). The cells for transplantation (eGFP-TEG3 or eGFP-NgR(Ecto)-TEG3) were suspended in L15 medium (Invitrogen) at 50,000 cells/ll and maintained in ice during the time of surgery. 30 min after the lesion, using a glass needle (100 lm internal diameter, Eppendorf, Hamburg, Germany) coupled to a 10 ll Hamilton syringe (Hamilton #701, Hamilton Co, NV, USA), 6 ll of the corresponding cell suspension was intraspinally injected (1 mm deep into the spinal cord, 2 injections of 3 ll each, one at each side 1 mm lateral to the lesion point), with a total of 150,000 cells per injection (300,000 cells/rat). A perfusion speed of 2 ll/min was controlled by an automatic injector (KDS 310 Plus, Kd Scientific, Holliston, MA, USA), and the needle tip was maintained inside the tissue 3 min after injection to avoid liquid reflux. A total of six rats were used (3 rats received eGFP-TEG3 cells, and the other 3 eGFP-NgR(Ecto)-TEG3 cells). The wound was sutured by planes and the animals allowed to recover in a warm environment. Bladders were expressed twice a day. To prevent infection, amoxicillin (500 mg/l) was given in the drinking water for one week.
Tissue processing
Seven days post-implantation, rats were deeply anaesthetized (pentobarbital 60 mg/kg b.w. i.p.) and intracardially perfused with 4 % paraformaldehyde in 0.1 M PBS. The spinal cord segment from 1.5 cm rostral to 1.5 cm caudal to the injection (±3 cm total length) was harvested and post-fixed in the same fixative solution for 24 h and cryopreserved in 30 % sucrose. For GFP-positive cell localization, 30 lm thick longitudinal cryostat sections of the spinal cord segment were obtained. Spinal cord sections of cell-transplanted rats were processed for immunohistochemistry against GFP and GFAP. Tissue sections were incubated with 0.1 M PBS Triton X-100, 5 % foetal bovine serum during 4 h and 24 h at room temperature with with primary antibodies at 4°C. After washing, sections were incubated for 2 h at room temperature with the secondary antibody. Slides were dehydrated and mounted with Citoseal 60 (Thermo Fisher Scientific, Madrid, Spain). For analysis, images (10 megapixels) were obtained with a digital camera (Leica DFC 550) attached to the microscope (Leica AF700). Starting from the injection points, 11 consecutive sections of the length of approximately 200 lm were captured. GFP-positive cells in each section were counted.
Statistical analysis
Summary data are expressed as mean ± S.E.M (standard error of the mean) of at least three independent experiments (unless indicated). Data were analysed using Bonferroni post hoc test (Multiple comparison test) using Prism 5 (Mac OsX, Grahpad). A value of **P \ 0.05 was considered statistically significant.
Results
Reduced migration and traction forces in cultured TEG cells mediated by CSPGs and OMgp
TEG3 is a clone OEC line that shows similar growth promoting potential to non-modified OECs (e.g., [35] . In addition, previously published data reported that TEG3 cell migration is inhibited by myelin [24] as happens with nonmodified OECs [25] . Because of the lamellipodial activity of the OECs that seems to play a crucial role in OEC migration [47] and regeneration properties [48] , we analysed the membrane dynamics in OECs over different substrates (Fig. 1 ). TEG3 cells growing on laminin-coated substrates showed a bipolar morphology with numerous dynamic filopodia and lamellipodia (Supplementary Movie 1). The migration of these cells is similar to those observed in cultured fibroblasts (e.g., NIH/3T3 fibroblasts; ATCC CRL-1568) with random trajectories (see below). LifeActeGFP transfected TEG3 cells showed an intense remodelling of the Actin cytoskeleton during migration (Supplementary Movie 2 and Fig. 1a) . Thus, video timelapse experiments used to analyse the dynamics of the cell membrane showed increased dynamics of TEG3 growing over laminin (Fig. 1a, d ) compared with TEG3 cells growing on CSPG (Fig. 1b, e) or OMgp-coated (Fig. 1c, f) substrates. This also correlates with decreased cell protrusions observed in GFP immunoreacted cells (Fig. 1a-c ) and in scanning electron microscopy (SEM) observations (Fig. 1g-i) .
Next, TEG3 migration over laminin, CSPG-, and OMgp-coated substrates was monitored for 20 h in video time-lapse experiments (20X objective; one frame every 8 min) (Fig. 2 and Supplementary Movies 3-5). A threeaxis plot (x/y position vs time (hours)) revealed higher motile persistence on laminin coated (Fig. 2d ) than on CSPG- (Fig. 2e) or OMgp-coated (Fig. 2f) substrates. Quantitatively, the migration speed of TEG3 s cells over laminin was 0.81 ± 0.03 lm/min. In contrast, TEG3 cells Increased migration of olfactory ensheathing cells 2723 growing over CSPG-or OMgp-coated substrates showed a dramatic decrease in the migrated speed ranging from 63 to 76 % (0.27 ± 0.05 lm/min (OMgp, 10 lg/ml) to 0.19 ± 0.02 lm/min (CSPG; 25 lg/ml). Mounting evidence demonstrates that cells generate traction forces against their substrate during adhesion and migration, and traction forces are used by cells to sense the extracellular matrix in healthy and unhealthy conditions (e.g., [49, 50] ). Thus, using traction force microscopy (TFM), we aimed to determine the distribution of traction forces in TEG cells cultured on a well-characterized polyacrylamide (PAA) gel, which is linearly elastic, optically clear, and suitable for protein conjugation ([51] see for details). Using TFM, we observed that cells seeded on laminincoated substrates transferred higher strain energy (0.01389 ± 0.004, PJ; n = 16) (Fig. 2h) to their underlying substrate than those seeded on CSPG-(0.00018 ± 0.0001, PJ; n = 35) (Fig. 2i) or OMgp-coated substrate (0.00032 ± 0.0001, PJ; n = 29) (Fig. 2j) (laminin vs CSPG t = 6.362 and laminin vs OMgp t = 6.086; P \ 0.05). Effects of ChABC treatment on TEG3 cell migration and traction forces over CSPG-containing substrates The bacterial enzyme ChABC liberates chondroitin suphate GAGs from CSPG core proteins to render a more permissive substrate for axonal outgrowth [34, 52] . ChABC acts on chondroitin 4-suphate, chondroitin 6-sulphate, and dermatan sulfated proteogycans, and acts very slowly on hyaluronate. This enzyme has been used to promote axon regeneration in lesioned spinal cord in single and combined treatments (e.g., [34, [53] [54] [55] ). In fact, ChABC has been used in combination with OECs [32, 56] , and the expression of ChABC has also been directed to Schwann cells [57] and astrocytes [58] with relevant results. In our study, TEG migration and traction forces were decreased by CSPGs (see above). Thus, we aimed to determine whether ChABC treatment affected intrinsic OEC migratory properties and whether it was able to rescue their migration when cultured over CSPGs (Fig. 3) . Control experiments demonstrated that ChABC treatment did not modify the migration or the traction forces of cultured TEGs over laminin (Fig. 3a, c and Supplementary Movie 6), myelin, or OMgp (not shown). TEG3 migration over CSPG-coated substrates was 0.19 ± 0.05 lm/min (CSPG; 25 lg/ml). A = 60 % increase in the migratory speed was observed after treatment with ChABC (0.48 ± 0.07 lm/ min) (Fig. 3b, c and Supplementary Movie 7) . F-actin and Vinculin staining on TEG3 cells growing on CSPG-coated substrates demonstrated increased lamellipodia and the presence of Vinculin-positive aggregates after ChABC treatment (Fig. 3d-i) . In parallel, these increased Vinculin aggregates correlated with increased traction force as determined with TFM (0.00179 ± 0.0004, PJ; n = 35) (Fig. 3j-k) . Generation and characterization of NgR(Ecto)-TEG3 cells TEG3 cell lines producing and secreting the extracellular domain (1-310 aa) of the NgR1 receptor were generated by lentiviral infection and selected with Blasticidin (see Methods for details). In addition, selected clones were infected with eGFP-expressing lentivirus (Fig. 4) . Clones ([95 % eGFP-NgR(Ecto)-TEG3) were selected by the expression levels of the ectodomain. With western blotting, we detected the ectodomain in both cell extracts and in cultures ( Fig. 4a and Supplementary Fig. S2 ). eGFP coexpression in NgR(Ecto) producing cells did not modify the expression of ectodomain (Fig. 4a-c) . In addition, eGFP-positive NgR(Ecto)-TEG3 cells maintained p75 or S100b expression (Fig. 4d, e) and displayed the range of morphologies (astrocyte-or Schwann cell-like) described for cultured primary OEC and TEG3 cells (Fig. 4f-i )(e.g., see also [24, 27] , for details).
TEG3-generated NgR(Ecto) blocks Nogo66-AP binding to Nogo receptor
As indicated above, OECs and TEG3s express all members of the Nogo receptor complex (e.g., [24, 25, 59] ). Thus, to determine whether the NgR(Ecto) produced by TEG3 cells was active, we incubated TEG3 cells (&75 % confluence) with Nogo66-AP in the absence or presence of NgR(Ecto)-containing solution (Fig. 5a-e) . After incubation, AP activity in treated cells was measured at 405 nm spectrophotometer (Fig. 5d, e) . Results revealed a decrease of &18 and &55 % in the OD values after incubation with 150 nM or 300 nM TEG-produced NgR(Ecto) (Fig. 5e ). In addition, we incubated with TEG3-generated NgR(Ecto) CGNs cultured on Poly-D-Lysine (Fig. 5f, g ), as well as cell membranes of Mock-and NogoA-transfected HEK293 cells (Fig. 5f, g ). Cultured CGNs were labelled using the TUJ-1 antibody. Neurite length of CGNs cultured over NogoA membranes was reduced to &40 % compared to Mock-transfected and Poly-D-Lysine values (Fig. 5g) when cultured over control HEK293 membranes (Membrane ? NgR(Ecto) 97.5 ± 11.52 vs Membrane ? Mock = 103 ± 13.82).
NgR(Ecto)-TEG3 cells overcome OMgp inhibition to cortical axons in microfluidic platforms
Compartmentalized neuronal cultures of lab-on-a-chip devices have been used for different studies in recent years (see [60] for a recent review). Due to this specific design, media located in the axonal reservoir are unable to diffuse to the soma reservoir [61] . Thus, we aimed to determine whether NgR(Ecto)-TEG3 cells are able to stimulate axon outgrowth over inhibitory MAI-containing substrates (Fig. 6) . Indeed, E15.5 cortical neurons cultured in one reservoir of the microfluidic platforms are able to cross the 900 lm long bridge channels in one week to reach the recipient or axonal reservoir (Fig. 6a) . In these conditions, cortical axons were able to spread in laminin-coated axonal reservoirs (Fig. 6a) expressing NgR receptor 3. Their axonal length was reduced by &25 % when OMgp was present as substrate in the axonal reservoir (Fig. 6b) . Next, we co-cultured eGFP-TEG3 and eGFP-Ngr(Ecto)-TEG3 cells in the axonal reservoir of parallel chips with E15.5 cortical neurons and coated with OMgp, as above (Fig. 6c,  d , e-g). Results indicated that eGFP-TEG3 was unable to statistically increase neurite length of cultured cortical neurons in the devices (Fig. 6c, g ). In contrast, eGFPNgR(Ecto)-TEG3 cells were able to increase by &24 % the axonal length of the cultured cortical neurons on OMgp (Fig. 6d, e-g ) (up to 95 % of the value obtained in the presence of laminin, Fig. 5g ). However, we were unable to observe a clear interaction between cortical axons and eGFP-NgR(Ecto)-TEG3 cells in our microfluidic devices, suggesting that these positive effects were mediated by the secreted NgR(Ecto) in the axonal compartment (Fig. 6e, f) .
Increased migration of NgR(Ecto)-TEG3 and NgR(Ecto)-treated TEG3 cells on MAI-coated substrates
Next we aimed to explore the migratory properties of NgR(Ecto)-TEG3 cells compared to TEG3 cells over inhibitory substrates and the specific effect of NgR(Ecto) on TEG3 cell migration over OMgp (Fig. 7) . Indeed, TEG3 migration over laminin, myelin-and OMgp-coated substrates was monitored for 20 h in video time-lapse experiments as above. Quantitatively, in these experiments the migration speed of TEG3s cells over laminin was 0.79 ± 0.05 lm/min (n = 38) (Fig. 7c ) and 0.82 ± 0.04 lm/min (n = 36) (Fig. 7f) . In contrast, TEG3 cells growing over myelin-or OMgp-coated substrates showed a decrease in migrating speed (0.3 ± 0.04 lm/min (Myelin; n = 35) (0.24 ± 0.02 lm/min (OMgp, 10 lg/ml; n = 35) as expected. NgR(Ecto)-TEG3 cells migrated as TEG3 cells over laminin (0.79 ± 0.05 lm/min; n = 38) (Fig. 7c ) but with increased speed over myelin (0.55 ± 0.04 lm/min; n = 37) (Fig. 7c and Supplementary Movie 8) and OMgp (0.47 ± 0.02 lm/min; n = 36) (Fig. 7f and Supplementary Movie 9) . In addition, when NgR(Ecto) was added to migrating TEG cells growing on OMgp-coated substrates, a 1.81-fold increase of the migratory speed was observed [0.49 ± 0.03 lm/min; n = 48 (TEG3 ? NgR(Ecto)] and 0.27 ± 0.02 lm/min; n = 37) [TEG without NgR(Ecto)] (Fig. 7g-l and Supplementary  Movies 10, 11 ). In addition, both TEG3 cells treated with NgR(Ecto) (Fig. 7k, n) and NgR(Ecto)-TEG3 cells (Fig. 7l,  o) growing over OMgp displayed relevant filopodia (Fig. 7k,  l) with abundant puncta-like staining of vinculin, suggesting increased focal contacts (Fig. 7n, o) compared to parallel TEG cell cultures (Fig. 7j, m) . In parallel, these data correlated with increased traction force on OMgp-coated treated with NgR(Ecto)-TEG3 (0.00274 ± 0.0006, PJ; n = 25) and NgR(Ecto) (0.00301 ± 0.0005, PJ; n = 28) (Fig. 8 ).
Increased migration of NgR(Ecto)-TEG3 cells in lesioned spinal cord
To further determine whether NgR(Ecto)-TEG3 cells also increased their migratory potential in vivo, 300,000 cells of eGFP-or NgR(Ecto)-TEG3 were implanted in injured spinal cords to analyse the capacity of these cells to integrate and migrate in the lesion model (Fig. 9) . A total of 6 rats were used (3 rats received eGFP-TEG3 cells, and the other 3 eGFP/NgR(Ecto)-TEG3). A week after transplantation, spinal cords were perfusion fixed and the localization and distribution of eGFP-positive cells were analysed (see Method for details). Eight representative slices were selected for analysis for each animal. The total number of eGFP-positive cells in the case of eGFP-TEG3s (6000 ± 250 cells/slice) was slightly less than that of eGFP-NgR(Ecto)-TEG3s (7000 ± 200 cells/slice). To assess the distance migrated, we counted the number of eGFP-positive cells in transversal stripe of about 200 lm in length starting from the injection point. Eleven lines or stripe caudal or rostral to the injection points were analysed (Fig. 8a, c, e) . Results revealed that most eGFP-TEG3 s were distributed near the injection point with the maximum cell percentage (&25 %) found in the section 400 lm rostral or caudal to these points (Fig. 9b, c, h ). Moreover, very few eGFP-TEG3 cells were observed more than 1,600-1,800 lm from the injection point (&8-9 stripe; Fig. 9h ). By contrast, eGFP-NgR(Ecto)-TEG3 cells were found in all 11 stripes analysed (Fig. 9d, e, h ) with a plateau in the number of cells (around 13-16 %) found in the first four sections (&800 lm) rostral or caudal to the injection points decreasing slowly in the following stripes (Fig. 9h) . In addition, increased numbers of eGFPNgR(Ecto)-TEG3 cells were also observed on the lesion side (Fig. 9f, g ).
Discussion
In physiological conditions, the migration of most cells occurs in an adhesion-dependent manner and involves the formation of FA at the membrane and the generation of mechanical forces via the actin-myosin network [62] . Traction force comes into play in the synchronization of these processes in different cell types (e.g., keratinocytes [62] , invasive tumor cells [63] , fibroblasts [64, 65] ) and olfactory ensheathing cells ( [24] and present results). Thus, the balance between traction force and adhesion strength can be understood as a direct indicator of cell migration capacity. Using TFM and single cell tracking, we showed the behaviour of TEG3 cells in a quantitative basis demonstrating that the increased traction force is sufficient to tilt the mechanical balance toward a pro-migratory phenotype of OECs [24] .
CSPGs as well as MAIs and their receptors modulate the establishment of this actin-myosin network as well as microtubule dynamics [5, 66] . Indeed, MAI-induced arrest of CNS axon growth is either induced after MAI receptor, the Ca 2? -dependent activation of the epidermal growth factor receptor (EGFr), or induced by sequential RhoA/ RhoK/LIM-kinase/cofilin phosphorylation, leading to actin depolymerization [67] . In parallel, microtubule stabilization is also compromised after exposure to MAIs [68] . Our results reinforce the notion that molecules present in myelin extracts act on Nogo receptor complex as well as on other receptors, and may modulate OEC cytoskeleton and FA distribution. OEC transplantation has been shown to promote regeneration and functional recovery in lesioned spinal cord [9, 10] . In that the regenerative properties of OECs are largely associated with their migration and lamellipodial dynamics (e.g., [23, 69] ) there is a considerable interest in enhancing OEC migratory capacity. In fact, it is assumed that OECs migrate ahead of growing axons and by secreting supporting factors (e.g., GDNF) [16, 28] , or with matrix metalloproteinase activity [70] aiding and promoting their elongation. These positive effects on axon elongation have also been described for DRG cells cultured on myelin in the presence of OECs (e.g., secreting BDNF) [28] . In a previous study, we demonstrated that OECs express the NgR receptor complex (NgR1, P75, Lingo1 and TROY) and that their migration is also impaired by myelin [24] . In addition, NogoA, Slit2, and fibulin-3 have been reported as inhibitors of OEC migration. However, the effects of CSPG on OEC migration have not been previously studied. Here, we described how CSPGs largely impair OEC migration by reducing the mechanical strain force that cells transmit to the coated substrate. This reduced force correlates well with the low number of vinculine-positive focal contacts and profound reorganization of F-Actin cortical cytoskeleton. In fact, a recent study described how CSPGs are also ligands for NgR1 and NgR3 MAI receptors [71] . TEG3 and NgR(Ecto)-TEG3 cells express NgR1 ( [24] and present results), which may explain some of the observed results that point to a functional redundancy between myelin inhibitors and CSPGs blocking OEC migration. However, because the binding region of CSPG to NgR1 is located in the Stalk region of the receptor, no relevant changes were observed between NgR(Ecto)-TEG3 and TEG3 cell migration over CSPG)(not shown).
Present results also reinforce the notion that most of the factors inhibiting axon elongation and regrowth after lesion may also affect OEC migration. In fact, to date all the described molecules inhibiting OEC migration-NogoA, fibulin-3, and Slit2-have been reported to be overexpressed in CNS scars after lesion [31, 72, 73] . Thus, in this scenario it is reasonable to consider that the combined treatment developed by Fouad et al, with ChABC, Schwann cell bridges, and OEC transplantation, may positively affect both OEC migration and axon regrowth [32] . Furthermore, secreted semaphorins (e.g., Sema3A) are expressed by OECs [74] and seem not to affect migration of OECs (J.A.D.R. unpublished results). In this respect, the single genetic ablation of MAIs [75] alone or with semaphorin receptors [76] is not strong enough to support axon regrowth after SCI. In contrast, it seems that blocking the MAI receptors NgR1 and NgR3 and CSPG receptors yields better results [71] . In light of the foregoing, we consider that a transplantation strategy with cells with endogenous neurotrophic support (producing GDNF or BDNF) and enhanced migratory properties in parallel with pharmacological treatment should be strongly considered as a potential combined therapy for SCI lesion. Indeed, in the present study we genetically modified TEG3 to express a soluble form of NgR1 receptor to overcome myelin-derived inhibition [36] . Results demonstrate that NgR(Ecto)-TEG3 cells migrate faster in vitro over OMgp and myelin-coated substrates in vivo as well after contusive lesions of the spinal cord. In addition, the recovery of migration capacity correlates with increased traction force observed in TFM experiments in NgR(Ecto)-TEG3s cells. However, the two recoveries (migration and strain forces) are not complete, suggesting that other factors are involved in this inhibition. Indeed, OECs might respond to other myelin-associated molecules (e.g., lipids [77] ) or express receptors other than NgR1 (e.g., LDL, receptor related protein 1) [78] , which could exert inhibitory action on axonal growth. However, whether these lipids could act on OECs is unknown and warrants further study. Yet another challenging question remains unsolved since NgR(Ecto)-TEG3 presents random migration as described for normal TEG3, which suggests that other strategies may be needed to generate a persistent and directed migration in the lesioned spinal cord using directed chemoattraction [24, 79] on specific functionalized biomaterials [80, 81] . In conclusion, we have demonstrated that OEC migration is impaired by CSPG and that an engineered OEC cell line to produce NgR ectodomain abolished the inhibitory properties of myelin extract and purified OMgp. These effects also correlate with increased migration after in vivo transplantation in contused spinal cord. Future experiments will be directed to overcoming CSPG inhibition in engineered cells to enhanced functional axon regeneration after lesion. 
